FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

In a recent study, precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein ...

KRAS G12C is one of several genetic mutations known to activate the KRAS protein, which drives tumor growth and progression. KRAS mutations are present in up to 45% of colorectal cancer cases, but ...

The KRAS G12D mutation is the most common oncogenic KRAS variant, identified in approximately 34% of pancreatic ductal adenocarcinoma cases, 12% of colorectal cancers and 4% of lung adenocarcinomas.

A three-dimensional image showing the human protein KRAS (blue) interacting with RAF1 (yellow), one of its main partners. The blue-to-red colour gradient indicates increasing potential for ...

One notoriously difficult-to-drug target is the protein KRAS, whose encoding gene is mutated in about one-quarter of all cancers. KRAS plays critical roles in cell growth and division ...

Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy ...

In a recent paper published in Nature, researchers from the University of Michigan have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and ...